Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors
Provided By GlobeNewswire
Last update: Oct 9, 2024
– Data show that p300 KAT inhibitor KB-9558 was highly selective against human papillomavirus (HPV) oncoproteins E6 and E7, and therefore drove anti-tumor effects –
NASDAQ:KRON (6/13/2025, 8:16:41 PM)
0.8926
+0.01 (+1.43%)
Find more stocks in the Stock Screener
KRON Latest News and Analysis
11 days ago - ChartmillWhich stocks are gapping on Thursday?The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs.
11 days ago - ChartmillThese stocks are moving in today's pre-market sessionThe US market is yet to commence its session on Thursday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
